1. TFS Corporate Presentation

2. It’s all about…

3.  Founded in 1996 with headquarters
in Sweden
 Largest privately owned European clinical
CRO
 Worldwide ranking no 14*
 ~ 550 employees
 Operations inspected by US FDA, EMA,
MHRA (UK) and MPA (Sweden)
 Geographical coverage in Europe,
USA and Japan
 Conducting clinical trials in 34 countries
worldwide (December 2012) **
 Projected revenue €50 million in 2013
The TFS Group - Facts and Figures
*) Based on the Scrip Clinical Research Report; “SCR 18 league
tables”, net revenue estimations 2011 for clinical CROs
**) 29 countries in Europe and Australia, Canada, USA, India and
Chile
Daniel Spasic
CEO and founder of TFS

4. TFS commitment to Quality
Year Type of Inspection Agency Critical Major Minor
2007 Phase I Unit/TFS System MPA 0 0 8
2008 Study Site MPA 0 0 7
2009
Phase I Unit/TFS System
(pre-NDA file)
FDA No 483
Phase I Unit/TFS System MPA 0 0 6
2010 Study Site EMA 0 0 7
Study Site JAZMP 0 0 6
CRO/TFS System MHRA 0 0 5
2011 Study Site MHRA 0 0 6
Study Site MHRA 0 0 6

5. TFS Group Organisation

6. TFS Geographical coverage
Regional Headquarters
Country Offices
TFS Clinical Trial Engagements
Headquarters

7. TFS Global HQ
 Sweden
TFS European Regional HQ
• North
• West & East
• South
TFS Country Offices
 United Kingdom
 USA
 Germany
 Spain
 Italy
 France
 The Netherlands
 Belgium
 Sweden
 Norway
 Denmark
 Finland
 Portugal
 Hungary
 Poland
 Czech Republic
 The Baltic (Estonia, Latvia, Lithuania)
TFS European Locations

8. Therapeutic Areas

9. Therapeutic Areas in all BA
(2012)*
*) Based on 800 clinical study protocols during 2012 in all
business areas; EXPLORE, DEVELOP and PEOPLE
Oncology 32%
CNS/Neurology 6%
Cardiovascular 9%
Endocrinology 3%
Musculoskeletal 5%
Gastrointestinal 2%
Dermatology 4%
Hematology 10%
Vaccine 3%
Immunology/
Inflammation 10%
Urology 1%
Respiratory 2%
Infection 2%
Medical Device 2%
Psychiatry 1%
Pain 1%
Ophthalmology 2%
Other 5%

10. Client Base

11. Distribution of Client Segments
(2012)*
*) Based on 203 unique client companies invoiced during 2012
**) “Other” includes: Generics, Functional Food and Diagnostics
Biotech 22%
Pharma SME 20%
Big Pharma 9%
Medical Device 7%
CRO 8%
Other 21%**
Academia 13%

12. Revenues per Client Segment
(2012)*
*) Based on 203 unique client companies invoiced during 2012
**) “Other” includes: Generics, Diagnostics, Nutrition, CROs and
Medical Device
Big Pharma 60%
Biotech 15%
Pharma SME 15%
Other** 7%
Academia 3%

13. 20 Largest Customers
(2012)

14. Why Customers Select TFS
Capacity to manage
global trials
 Navigate through complex regulatory
landscape
 Balanced geographical footprint throughout
European countries and USA
Mid-sized organisation hosting all
clinical development areas
 Possibility to follow the development from
Phase I to Post-launch trials
 High competence and therapeutic area
knowledge among the TALs
Well positioned within the CRO
business
 Not too large to lose customer attention, not
too small to pose a risk
 Price for services meets expectations
by customers
Experience, track-record and
reputation
 Consistent proven track-record in
operational deliverables
 Strong references among the leading life
science sponsors

15. Business Solutions

16. Phase 0/I and PoC trials;
~ 10 employees
Phase II – IV trials; 34 countries world-wide (2011)
~ 270 employees
Clinical research professionals within FSP models;
~ 220 employees
Specialist training for clinical research professionals;
www.tfsacademy.com
~ 5 employees
Four Dedicated Business Areas

17. www.tfscro.com